NCT04079166
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04079166
Title SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Scancell Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.